October I 2023

During a Targeted Oncology™ Case-Based Roundtable™ event, Millie S. Das, MD, and participants discussed considerations for managing toxicities of amivantamab and mobocertinib for patients with EGFR exon 20 insertion–positive non–small cell lung cancer.

In a live virtual event, Yasir Y. Elamin, MD, discussed biomarker testing and management of non–small cell lung cancer (NSCLC) and a related patient case with participating physicians.

During a Targeted Oncology™ Clinical Case Forum event in partnership with the Nevada Oncology Society, Jonathan Riess, MD, MS, summarized the outcomes and impact of the PACIFIC and ADAURA trials in patients with nonmetastatic non–small cell lung cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Laura Huppert, MD, and participants discussed treatment approaches for a patient HR-positive, HER2-negative breast cancer with liver and lung metastases who continues to progress on endocrine therapy and CDK4/6 inhibitors.

During a Targeted Oncology™ Case-Based Roundtable™ event, Rebecca Arend, MD, and participants discussed the use of single-agent immune checkpoint inhibitor as opposed to pembrolizumab plus lenvatinib in a patient with recurrent mismatch-repair deficient endometrial cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Benjamin Garmezy, MD, discussed trial data that guides when to use cabazitaxel for patients with metastatic castration-resistant prostate cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Abdulraheem Yacoub, MD, and participants discussed the process of initiating JAK inhibitor therapy for a patient with primary myelofibrosis.

During a Targeted Oncology™ Case-Based Roundtable™ event, Daniel George, MD, discussed the CheckMate 9ER trial in terms of bone, liver, and lung metastases and other subgroups in patients with advanced clear cell renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Leslie M. Randall, MD, MAS, evaluated the outcomes of the PRIMA/ENGOT-OV26/GOG-3012 study of niraparib as primary maintenance therapy for patients with ovarian cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Nicholas Short, MD, and participants discussed which patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia they would treat with inotuzumab ozogamicin.

During a Targeted Oncology™ Case-Based Roundtable™ event, Matthew A. Lunning, DO, and participants discussed how they approach treatment for a patient with diffuse large B-cell lymphoma who relapsed 8 months after primary therapy.

Wendi Waugh, BS, RT(R)(T), CMD, CTR, discussed what community practices can expect regarding a patient’s financial toxicity and the creative solutions available to ease that financial burden.

At a live virtual event, Jane Lowe Meisel, MD, provided insights into the latest practice updates for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

The addition of PARP inhibitors for the treatment of patients with BRCA-mutated advanced ovarian cancer has provided clinicians with a stronger set of treatment options. Looking at how the BRCA mutation responds to these inhibitors is then vital to deciding the patient’s treatment path.